Peripheral Arterial Disease – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of Peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed incidence of PAD for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.
All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s PAD forecast answers the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with PAD?
- Of all people with PAD, how many in each country have been formally diagnosed?
- Of all people diagnosed with PAD, how many in the mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PAD over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following PAD subpopulations:
- Total prevalent cases.
- Diagnosed prevalent cases
Note: Coverage may vary by country.
Ravdeep Kaur, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. She holds a master’s degree in public health from the School of Public Health at the Post-Graduate Institute of Medical Education and Research and a bachelor’s degree in dental surgery from Rajiv Gandhi University of Health Sciences in India. Prior to joining DRG, she was a consultant for the Reproductive, Maternal, Child, and Adolescent Health Program, funded by the U.S. Agency for International Development.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.